Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention

Inclusion Criteria: 1. At least 18 years of age or older 2. Have documented IBD based on usual diagnostic criteria including clinical symptoms and findings from endoscopy, radiology studies, and histology 3. Initiating treatment with vedolizumab 4. Have access to a mobile smartphone (iPhone 7 or later; Android release date 2012 or later) with reliable data and/or Wi-Fi access 5. Ability to understand the protocol and provide informed consent in English or Spanish Exclusion Criteria: 1. Inability to speak and read English or Spanish 2. Unable to comply with the study protocol including inability to access the internet and/or inadequate access to a smart device 3. Unable to access vedolizumab due to insurance restrictions 4. Unable to follow up at respective sites due to insurance restrictions or other barriers (i.e., distance from patient's home to study site) 5. Presence of an ileostomy, colostomy, ileoanal pouch anastomosis, or ileorectal anastomosis 6. Imminent surgery (within the next 60 days) 7. History of short bowel syndrome 8. Uncontrolled medical or psychiatric disease at the opinion of the investigator 1. Degenerative neurologic condition 2. Unstable angina 3. Symptomatic peripheral vascular disease 4. Malignancy within the last 2 years (excluding squamous or basal cell cancers of the skin) 5. Poorly controlled depression, mania, and schizophrenia 6. Serious active infection requiring antimicrobial therapy (excluding CD patients with perianal CD on antibiotics)